ASH 2013: Emergent's otlertuzumab maintains ORR lead in Phase II
This article was originally published in Scrip
Executive Summary
Updated Phase II results for otlertuzumab from Emergent BioSolutions plus Teva Pharmaceutical's Treanda (bendamustine), which were presented at the American Society of Hematologists (ASH) Annual Meeting on 8 December, show that the CD37-targeting monoclonal antibody is maintaining its lead over Treanda alone.